Cargando…

Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study

Antithyroid drugs are widely used in the therapy of Graves’ disease (GD), and methimazole (MMI) is preferred for treatment of pediatric GD. The recommended initial dosage of MMI is 0.5–1.0 mg/kg/d for pediatric GD, although there are few studies on the optimal MMI dosage for initial treatment in chi...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, Rie, Nakagawa, Yuichi, Nagata, Eiko, Satake, Eiichiro, Sano, Shinichiro, Yamaguchi, Rie, Fujisawa, Yasuko, Masui, Ayako, Nakanishi, Toshiki, Endo, Akira, Kagawa, Jiro, Ohzeki, Takehiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society for Pediatric Endocrinology 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687628/
https://www.ncbi.nlm.nih.gov/pubmed/23926385
http://dx.doi.org/10.1297/cpe.19.101
_version_ 1782273961657106432
author Matsushita, Rie
Nakagawa, Yuichi
Nagata, Eiko
Satake, Eiichiro
Sano, Shinichiro
Yamaguchi, Rie
Fujisawa, Yasuko
Masui, Ayako
Nakanishi, Toshiki
Endo, Akira
Kagawa, Jiro
Ohzeki, Takehiko
author_facet Matsushita, Rie
Nakagawa, Yuichi
Nagata, Eiko
Satake, Eiichiro
Sano, Shinichiro
Yamaguchi, Rie
Fujisawa, Yasuko
Masui, Ayako
Nakanishi, Toshiki
Endo, Akira
Kagawa, Jiro
Ohzeki, Takehiko
author_sort Matsushita, Rie
collection PubMed
description Antithyroid drugs are widely used in the therapy of Graves’ disease (GD), and methimazole (MMI) is preferred for treatment of pediatric GD. The recommended initial dosage of MMI is 0.5–1.0 mg/kg/d for pediatric GD, although there are few studies on the optimal MMI dosage for initial treatment in children. We retrospectively compared the efficacy of different doses of MMI in 35 children with GD. Eight children were excluded due to lack of follow-up, etc. The remaining 27 children were divided into a high-dose group (HD; MMI≥0.7 (0.85 ± 0.13) mg/kg/d, n=8) and a low-dose group (LD; MMI<0.7 (0.51 ± 0.12) mg/kg/d, n=19), and we compared the time needed for the serum FT4 levels to normalize (≤1.6 ng/dl) between the groups. There were no significant differences between the FT4 levels (HD: 5.5 ± 2.8 ng/dl; LD: 5.0 ± 2.4 ng/dl p=0.59) or thyroid stimulating hormone receptor antibody levels (HD: 56.2 ± 29.3%; LD: 60.9 ± 27.2% p=0.69) between the groups before treatment. The mean time required to normalize the FT4 levels was 22.5 ± 7.4 d in the HD group and 28.8 ± 16.2 d in the LD group (p=0.30). In addition, no other factor influenced the time to efficacy of MMI. A dose of MMI<0.7 (0.51 ± 0.12) mg/kg/d appears to as effective as a higher dose in normalizing the serum FT4 level in children with mild or moderate GD.
format Online
Article
Text
id pubmed-3687628
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher The Japanese Society for Pediatric Endocrinology
record_format MEDLINE/PubMed
spelling pubmed-36876282013-08-07 Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study Matsushita, Rie Nakagawa, Yuichi Nagata, Eiko Satake, Eiichiro Sano, Shinichiro Yamaguchi, Rie Fujisawa, Yasuko Masui, Ayako Nakanishi, Toshiki Endo, Akira Kagawa, Jiro Ohzeki, Takehiko Clin Pediatr Endocrinol Original Article Antithyroid drugs are widely used in the therapy of Graves’ disease (GD), and methimazole (MMI) is preferred for treatment of pediatric GD. The recommended initial dosage of MMI is 0.5–1.0 mg/kg/d for pediatric GD, although there are few studies on the optimal MMI dosage for initial treatment in children. We retrospectively compared the efficacy of different doses of MMI in 35 children with GD. Eight children were excluded due to lack of follow-up, etc. The remaining 27 children were divided into a high-dose group (HD; MMI≥0.7 (0.85 ± 0.13) mg/kg/d, n=8) and a low-dose group (LD; MMI<0.7 (0.51 ± 0.12) mg/kg/d, n=19), and we compared the time needed for the serum FT4 levels to normalize (≤1.6 ng/dl) between the groups. There were no significant differences between the FT4 levels (HD: 5.5 ± 2.8 ng/dl; LD: 5.0 ± 2.4 ng/dl p=0.59) or thyroid stimulating hormone receptor antibody levels (HD: 56.2 ± 29.3%; LD: 60.9 ± 27.2% p=0.69) between the groups before treatment. The mean time required to normalize the FT4 levels was 22.5 ± 7.4 d in the HD group and 28.8 ± 16.2 d in the LD group (p=0.30). In addition, no other factor influenced the time to efficacy of MMI. A dose of MMI<0.7 (0.51 ± 0.12) mg/kg/d appears to as effective as a higher dose in normalizing the serum FT4 level in children with mild or moderate GD. The Japanese Society for Pediatric Endocrinology 2010-12-29 2010-10 /pmc/articles/PMC3687628/ /pubmed/23926385 http://dx.doi.org/10.1297/cpe.19.101 Text en 2010©The Japanese Society for Pediatric Endocrinology http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
spellingShingle Original Article
Matsushita, Rie
Nakagawa, Yuichi
Nagata, Eiko
Satake, Eiichiro
Sano, Shinichiro
Yamaguchi, Rie
Fujisawa, Yasuko
Masui, Ayako
Nakanishi, Toshiki
Endo, Akira
Kagawa, Jiro
Ohzeki, Takehiko
Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
title Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
title_full Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
title_fullStr Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
title_full_unstemmed Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
title_short Initial Treatment of Pediatric Graves’ Disease with Methimazole: A Retrospective Follow-up Study
title_sort initial treatment of pediatric graves’ disease with methimazole: a retrospective follow-up study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687628/
https://www.ncbi.nlm.nih.gov/pubmed/23926385
http://dx.doi.org/10.1297/cpe.19.101
work_keys_str_mv AT matsushitarie initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT nakagawayuichi initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT nagataeiko initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT satakeeiichiro initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT sanoshinichiro initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT yamaguchirie initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT fujisawayasuko initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT masuiayako initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT nakanishitoshiki initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT endoakira initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT kagawajiro initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy
AT ohzekitakehiko initialtreatmentofpediatricgravesdiseasewithmethimazolearetrospectivefollowupstudy